The Dr. Pat Show: Talk Radio to Thrive By!: Good News Segment: Seema Verma-Medicare enrollment ends December 7, 2018 & Ray Kerins:The Alka-Rocket Challenge for students

The Dr. Pat Show: Talk Radio to Thrive By!: Good News Segment: Seema Verma-Medicare enrollment ends December 7, 2018 & Ray Kerins:The Alka-Rocket Challenge for students

  10/24/2018  11:30 am PDT

If you have a Medicare health or prescription drug plan, you only have until the end of Open Enrollment, December 7, to make changes to your 2019 plan. Even if you are happy with your current Medicare coverage, you might find something better. Every year Medicare health plans change in cost, coverage, and participating providers. In fact, the projected 2019 average basic monthly premium for a Part D prescription drug plan is at the lowest rate since 2012! If you miss the Open Enrollment deadline, most people will have to wait a full year before they can make changes to their plans. Medicare Open Enrollment began on Monday, October 15 and ends at midnight on Saturday, December 7. 

 

The Alka-Rocket Challenge: Students compete to blast their way into the Guinness World Records and highlight the importance of stem education.  
The Bayer Alka-Rocket Challenge will be held December 12, 2018 at Florida’s Kennedy Space  Center

HOST

dr pat baccili host of the dr pat show and transformation talk radio network

Dr. Pat Baccili

Dr. Pat Baccili helps individuals and organizations break through their limiting Crust so they can reach their unlimited potential. Her specialty is assisting people face t...

Find out more »

GUESTS

 Seema  Verma

Seema Verma

As Administrator of CMS, Ms. Verma oversees one of the largest federal agencies that administers vital healthcare programs to over 100 million Americans. Before becoming CMS...

Find out more »
Raymond Kerins-Alka Rocket Challenge-transformation talk radio

Raymond Kerins

Ray Kerins is Senior Vice President of Corporate Affairs for Bayer. He manages all communications, government relations, policy and advocacy for Bayer’s four main busi...

Find out more »